Myovant fiscal year
WebJan 10, 2024 · BASEL, Switzerland, Jan. 10, 2024 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining care for women and for men, … WebOct 26, 2024 · Second fiscal quarter 2024 total revenues of $77.9 million; net product revenue from U.S. sales of ORGOVYX® of $18.7 million and MYFEMBREE® of $0.6 millionEstimated 8,000 cumulative ...
Myovant fiscal year
Did you know?
WebMyovant Sciences Announces Financial Results for Third Quarter of Fiscal Year 2024 and Corporate Updates January 26, 2024 Third fiscal quarter 2024 total revenues of $54.4 … WebJul 27, 2024 · Myovant 2024 fiscal year is off to a strong start, marked by significant volume driven growth for both ORGOVYX and Myfembree and with regulatory advances that enable us to reach more patients...
WebMar 31, 2024 · Purchase Agreement. In the first quarter of fiscal year 2024, Myovant further strengthened its balance sheet, raising $22.5 million with the completion under the ATM program. About Relugolix Relugolix is an oral, once-daily, small molecule that acts as a gonadotropin-releasing hormone, or GnRH, receptor antagonist that has been evaluated
WebApr 13, 2024 · Myovant Sciences has a 1-year low of $7.67 and a 1-year high of $27.06. The company has a market capitalization of $2.62 billion, a P/E ratio of -14.13 and a beta of 2.17. ... On average, research analysts expect that Myovant Sciences will post -1.82 earnings per share for the current fiscal year. Insiders Place Their Bets. WebAug 5, 2024 · Myovant to host conference call and webcast on Monday, August 8, 2024, at 8:30 a.m. Eastern Time / 5:30 a.m. Pacific Time; ... A further description of risks and uncertainties can be found in Pfizer’s Annual Report on Form 10-K for the fiscal year ended December 31, ...
WebMay 11, 2024 · BASEL, Switzerland, May 11, 2024 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining care for women and for men, today announced corporate updates and...
WebJul 28, 2024 · Myovant generated a net loss of $61.7 million or $0.67 per share in the first quarter of 2024,, compared to a net loss of $32.9 million or $0.37 per share in the prior year quarter. Looking ahead ... google sheets list in a cellWebMyovant Sciences Announces Financial Results for Second Quarter of Fiscal Year 2024 and Corporate Updates October 26, 2024 Second fiscal quarter 2024 total revenues of $77.9 … google sheets list in cellWebAug 5, 2024 · BASEL, Switzerland and NEW YORK, [August 5] (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV) and Pfizer Inc. (NYSE: PFE) today announced that the … chicken fried steak benedictWebApr 11, 2024 · Myovant Sciences has a one year low of $7.67 and a one year high of $27.06. The company has a market capitalization of $2.62 billion, a PE ratio of -14.13 and a beta of 2.17. The company’s 50 ... google sheets link to another workbookWebBASEL, Switzerland , Nov. 12, 2024 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining care for women and for men, today … google sheets live crypto pricesWebMay 26, 2024 · A further description of risks and uncertainties can be found in Pfizer’s Annual Report on Form 10-K for the fiscal year ended December 31, 2024 and in its subsequent reports on Form 10-Q, including in the sections thereof captioned “Risk Factors” and “Forward-Looking Information and Factors That May Affect Future Results”, as well as … google sheets link to sheetWebFeb 11, 2024 · Myovant Sciences Announces Corporate Updates and Financial Results for Third Quarter of Fiscal Year 2024. February 11, 2024 06:55 ET ... Third Quarter Fiscal Year 2024 Financial Summary. google sheets link to cell in another sheet